MetLife Investment Management LLC Cuts Position in ASP Isotopes Inc. (NASDAQ:ASPI)

MetLife Investment Management LLC lowered its position in ASP Isotopes Inc. (NASDAQ:ASPI) by 18.3% in the fourth quarter, Holdings Channel reports. The fund owned 25,988 shares of the company’s stock after selling 5,834 shares during the period. MetLife Investment Management LLC’s holdings in ASP Isotopes were worth $118,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the company. Barclays PLC raised its holdings in shares of ASP Isotopes by 438.5% in the 3rd quarter. Barclays PLC now owns 72,330 shares of the company’s stock valued at $201,000 after purchasing an additional 58,897 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in ASP Isotopes by 854.6% in the fourth quarter. JPMorgan Chase & Co. now owns 211,893 shares of the company’s stock valued at $960,000 after buying an additional 189,697 shares during the last quarter. Avantax Advisory Services Inc. acquired a new stake in ASP Isotopes in the fourth quarter valued at $45,000. Rhumbline Advisers lifted its holdings in ASP Isotopes by 69.1% during the 4th quarter. Rhumbline Advisers now owns 60,363 shares of the company’s stock worth $273,000 after buying an additional 24,664 shares during the last quarter. Finally, Russell Investments Group Ltd. boosted its position in shares of ASP Isotopes by 56.3% during the 4th quarter. Russell Investments Group Ltd. now owns 10,221 shares of the company’s stock worth $46,000 after acquiring an additional 3,682 shares in the last quarter. Hedge funds and other institutional investors own 16.80% of the company’s stock.

Insider Buying and Selling at ASP Isotopes

In other news, COO Robert Ainscow sold 66,666 shares of the company’s stock in a transaction on Tuesday, April 15th. The shares were sold at an average price of $5.75, for a total value of $383,329.50. Following the completion of the transaction, the chief operating officer now owns 1,553,326 shares in the company, valued at approximately $8,931,624.50. This represents a 4.12 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Paul Elliot Mann sold 316,666 shares of the stock in a transaction on Thursday, April 17th. The shares were sold at an average price of $5.62, for a total transaction of $1,779,662.92. Following the completion of the transaction, the chief executive officer now directly owns 7,315,454 shares in the company, valued at $41,112,851.48. This trade represents a 4.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 766,667 shares of company stock worth $4,358,502 over the last three months. Insiders own 21.40% of the company’s stock.

ASP Isotopes Trading Up 10.7 %

ASPI opened at $6.42 on Friday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 7.54 and a current ratio of 7.55. ASP Isotopes Inc. has a one year low of $1.86 and a one year high of $9.33. The company has a market cap of $481.90 million, a P/E ratio of -10.52 and a beta of 3.40. The business’s 50-day simple moving average is $4.96 and its 200-day simple moving average is $5.40.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.